

1 **The effect of sample medication use on subsequent anti-VEGF agent selection for**  
2 **neovascular age-related macular degeneration**

3 Karen M. Wai<sup>1</sup>, Tedi Begaj<sup>1</sup>, Sachi Patil<sup>2</sup>, Evan Chen<sup>3</sup>, John B. Miller<sup>1</sup>, Jan Kylstra<sup>1</sup>,  
4 Mary E. Aronow<sup>1</sup>, Lucy H. Young<sup>1</sup>, Rachel Huckfeldt<sup>1</sup>, Deeba Husain<sup>1</sup>, Leo A. Kim<sup>1</sup>,  
5 Demetrios G. Vavvas<sup>1</sup>, Dean Elliott<sup>1</sup>, Shizuo Mukai<sup>1</sup>, Evangelos S. Gragoudas<sup>1</sup>, Nimesh  
6 A. Patel<sup>1</sup>, Lucia Sobrin<sup>1</sup>, Joan W. Miller<sup>1</sup>, Ravi Parikh<sup>\*2, 4</sup>, David M. Wu<sup>\*1</sup>

7  
8 <sup>1</sup> Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard  
9 Medical School, Boston, Massachusetts

10 <sup>2</sup> Department of Ophthalmology and Visual Sciences, New York University School of  
11 Medicine, New York, New York

12 <sup>3</sup> Department of Ophthalmology, University of California, San Francisco, California

13 <sup>4</sup> Manhattan Retina and Eye Consultants, New York, New York

14  
15 \*Co-senior authors listed in alphabetical order

16 **Running head:** Role of sample medication use in anti-VEGF agent selection

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

32 **Corresponding Author:**

34 David M. Wu, MD PhD  
35 Assistant Professor of Ophthalmology  
36 Retina Service, Massachusetts Eye and Ear  
37  
38 243 Charles St, Boston, MA, 02114  
39 david\_wu@meei.harvard.edu  
40 Tel: (617) 573-5550

42 **Abstract**

43 **Purpose:** To examine the effect of medication sample use (ranibizumab or aflibercept)  
44 on future anti-vascular endothelial growth factor (VEGF) agent selection in neovascular  
45 age-related macular degeneration (nvAMD).

46 **Design:** Retrospective cohort study.

47 **Methods:** nvAMD patients who underwent an initial anti-VEGF injection with a sample  
48 medication were compared to nvAMD control patients who never received a medication  
49 sample. Charts from 2017 through 2020 were reviewed for data regarding  
50 demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups.  
51 Anti-VEGF agent selection for the first four injections and at one year were examined in  
52 both the sample and control groups.

53 **Results:** Adherence to the initial agent was high between first and subsequent  
54 injections (2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup> injection, and 1 year) in both sample (96.2%, 95.9%, 91.9%,  
55 93.4%, respectively) and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively).  
56 Bevacizumab usage was significantly lower among eyes receiving samples relative to  
57 controls at the second (1.9% vs. 38.7%,  $p<0.001$ ), third (3.1% vs. 41.3%,  $p<0.001$ ),  
58 fourth injections (4.7% vs. 40.4%,  $p<0.001$ ), and at 1 year (0% vs. 33.8%,  $p<0.001$ ).  
59 Aflibercept usage was significantly higher in sample eyes relative to controls at the  
60 second (78.3% vs. 43.4%,  $p<0.001$ ), third (76.3% vs. 41.5%,  $p<0.001$ ), and fourth  
61 injections (76.7% vs. 43.4%,  $p<0.001$ ), and at 1 year (77.0% vs. 52.7%,  $p<0.001$ ).

62 **Conclusions:** Eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept)  
63 for their initial injection were less likely to receive bevacizumab at future visits relative to  
64 eyes that did not receive an anti-VEGF sample, even after one year of treatment.

## 65 **Introduction**

66           Neovascular age-related macular degeneration (nvAMD) is a rapidly progressive  
67 disease that requires early initiation of treatment to prevent irreversible anatomical and  
68 functional loss. A recent study demonstrated that a 2-week delay in the administration of  
69 anti-vascular endothelial growth factor (anti-VEGF) after initial diagnosis is associated  
70 with worse visual outcomes.<sup>1</sup> Additional research has demonstrated improved visual  
71 outcomes for nvAMD with a shorter time span between symptom presentation and  
72 treatment.<sup>2</sup> Unfortunately, the initiation of treatment for patients with nvAMD is often  
73 delayed due to insurance prior-authorization (PA) requirements. PAs can inconvenience  
74 patients, complicate the timely initiation of care and have been shown to increase rates  
75 of treatment abandonment in other specialties.<sup>3,4</sup>

76           Medication samples represent a convenient, no-cost option to immediately  
77 provide treatment to patients with nvAMD while PA requests are pending. However, it is  
78 well established in medicine that samples can influence long-term physician prescribing  
79 behaviors.<sup>5</sup> Additionally, sample availability often skews towards expensive branded  
80 medications.<sup>5,6</sup> For nvAMD treatment, Bevacizumab (Avastin; Genentech, South San  
81 Francisco, CA) is the least expensive anti-VEGF agent. Initially a chemotherapy  
82 medication, it was repurposed as an intravitreal injection and used as an off-label drug  
83 by ophthalmologists, which enables a relatively low-cost of the drug at approximately  
84 \$50 per 1.25 mg dose when mixed by a local compounding pharmacy.<sup>7</sup> Because of the  
85 nature by which it is supplied, there are no samples of bevacizumab. Brand name on-  
86 label medications including ranibizumab (Lucentis; Genentech, South San Francisco,  
87 CA) and aflibercept (Eylea; Regeneron, Tarrytown, NY) have higher costs, with a single

88 vial costing roughly \$1716.55 (0.5mg/0.05ml) and \$1876.88 (2.0mg/0.5ml)  
89 respectively.<sup>8</sup> Both ranibizumab and aflibercept are approved by the Food and Drug  
90 Administration (FDA) for the treatment of nvAMD, and available as samples as a  
91 courtesy from their respective pharmaceutical companies.

92         Increasing drug costs are a significant concern as utilization of anti-VEGF agents  
93 is rising in the United States. Furthermore, nvAMD accounts for nearly two thirds of anti-  
94 VEGF utilization.<sup>9</sup> With the large price discrepancies between anti-VEGF medication  
95 options and the chronic nature of anti-VEGF treatment, the availability of samples may  
96 have significant ramifications on administration patterns and cost of care. Anti-VEGF  
97 medications are administered by the physician in clinic (i.e. Medicare Part B not D)  
98 under a model where the initial capital cost is placed on the physicians/clinic in the “buy  
99 and bill” model.<sup>6,10</sup> Thus, when presented with a new nvAMD patient, the physician  
100 must either defer treatment until prior authorization can be obtained, treat with a  
101 medicine (such as bevacizumab) and shoulder the cost should reimbursement later be  
102 denied, or if available, use an on-label sample which allows prompt treatment at no  
103 initial cost. There is no pre-existing literature on intravitreal anti-VEGF sample usage  
104 among ophthalmologists and how it may relate to future anti-VEGF selection. Therefore,  
105 the goal of our study is to determine how initial utilization of anti-VEGF samples affects  
106 subsequent anti-VEGF agent selection for patients with nvAMD.

107

## 108 **Methods**

109         A retrospective cohort study was conducted at a single institution, Massachusetts  
110 Eye and Ear (MEE). This study was approved by the institutional review board of the

111 Massachusetts General Hospital and Partners Healthcare (IRB # 2021P000301) and is  
112 compliant with the Declaration of Helsinki and Health Insurance Portability and  
113 Accountability Act regulations.

114 Patients with an ICD-9 or ICD-10 code for nvAMD who underwent their first anti-  
115 VEGF injection at MEE between January 2017 and December 2020 were identified.  
116 Eyes were included if they received a minimum of 2 anti-VEGF injections. Only one eye  
117 from each patient was included in the study; if both eyes met inclusion criteria, one eye  
118 was selected randomly to be included.

119 Billing codes were used to identify if a patient received a sample anti-VEGF  
120 medication with ranibizumab or aflibercept as their first injection at MEE. Patients were  
121 excluded if there was any history of prior injections at an outside institution or if there  
122 were any pre-existing indications that may have required anti-VEGF therapy (e.g.  
123 diabetic macular edema, retinal vein occlusion with macular edema). One-hundred and  
124 six patients fit this inclusion criteria for the sample group.

125 The control group was comprised of patients with nvAMD who did not receive a  
126 sample medication for their first injection, but rather an insurance-approved anti-VEGF  
127 agent. To account for variation between the sample and control patients among different  
128 MEE attendings at three MEE satellite facilities where samples are available, control  
129 patients were matched by both treating attending and location of injection to the sample  
130 population. Only patients from MEE attendings who injected both samples and  
131 insurance-covered medications, and who injected both on and off-label medications  
132 were included in the study. The control population consisted of several hundred  
133 patients; thus, a random sequence generator was used to randomize the patients, and

134 the first 106 patients who met inclusion criteria were included in the study. Sample  
135 patients had similar exclusion criteria applied to them. Patients seen at MEE satellite  
136 locations who did not have access to sample injections were also excluded from the  
137 study.

138 For all patients who met inclusion criteria, the following was collected: patient  
139 demographics, date of diagnosis relative to first injection, anti-VEGF agent selected for  
140 their first four injection visits and whether the agent was a sample or insurance-covered,  
141 visual acuities at each visit injection visit, and what agent was used at the one year time  
142 point if available. Date of first retina specialist evaluation for nvAMD was recorded.  
143 Insurance data was collected and divided into Medicare vs. Private/Medicare  
144 Advantage; this stratification was performed as Medicare does not typically require prior  
145 authorization for anti-VEGF injections. Adherence at each visit was calculated as a  
146 percentage of patients who received the same agent at that particular injection visit that  
147 they received at their first injection visit.

148 For statistical analysis, multivariate analysis taking into account gender, age,  
149 race, insurance, and location was used to compare the baseline demographics between  
150 the two groups. The proportion of patients receiving each agent was calculated at each  
151 of the time points: initial injection, second injection, third injection, fourth injection, and  
152 one year. Chi-square test for independence of proportions was used to compare anti-  
153 VEGF agent selection at each time point between the groups. An alpha of 0.05 was  
154 used as the threshold for statistical significance. Independent t-tests were used to  
155 compare time from visit with a retina specialist to first injection. Snellen acuities were

156 converted to LogMAR, and acuities were compared between groups with independent t-  
157 tests. P values less than  $<0.05$  were considered significant.

158

## 159 **Results**

### 160 *Baseline demographics*

161 One hundred and six eyes from 106 patients were identified who received a  
162 medication sample (either ranibizumab or aflibercept) as their initial anti-VEGF injection.  
163 Of these 106 sample patients, 68 (64.2%) were female. The average age was 79.7  
164 years [standard deviation (SD): 8.2 years], and 87.7% of patients were white. The  
165 control population consisted of patients who received only insurance-covered anti-  
166 VEGF injections for nvAMD, without any sample utilization in their treatment course. Of  
167 these 106 control patients, 69 (65.1%) were female with an average age of 79.2 years  
168 (SD: 8.5 years). The majority of patients (82.1%) were white (**Table 1**).

169 With multivariate analysis, there were no significant baseline differences between  
170 the sample population and control population in gender ( $p=0.53$ ), age ( $p=0.89$ ), race  
171 ( $p=0.10$ ), or insurance ( $p=0.06$ ). Patients in the control group were matched by both  
172 attending and location to patients in the sample group; all patients in this study were  
173 evaluated at one of three separate satellite locations within a single institution by 10  
174 different retina specialists (**Table 1**).

### 175 *Anti-VEGF agent selection*

176 In the 106 patients within the sample population, 22 (20.8%) patients received a  
177 sample injection of ranibizumab and 84 patients (79.2%) received a sample injection of  
178 aflibercept. At the second injection visit for the sample population ( $n=106$ ), 2 patients

179 (1.9%) received bevacizumab, 21 patients (19.8%) received ranibizumab, and 83  
180 patients (78.3%) received aflibercept. At the third injection visit (n=97), 3 patients (3.1%)  
181 received bevacizumab, 20 patients (20.6%) received ranibizumab, and 74 received  
182 (76.3%) received aflibercept. At the fourth injection visit (n=86), 4 patients (4.7%)  
183 received bevacizumab, 16 patients (18.6%) received ranibizumab, and 66 patients  
184 (76.7%) received aflibercept. At one year (n=61), 0 patients (0%) received  
185 bevacizumab, 14 patients (23.0%) received ranibizumab, and 47 (77.0%) received  
186 aflibercept (**Table 2**).

187 For the first injection in the control population (n=106), 43 patients (40.6%)  
188 initially received bevacizumab, 18 patients (17.0%) received ranibizumab, and 45  
189 patients (42.4%) received aflibercept. At the second injection visit for the control  
190 population (n=106), 41 patients (38.7%) received bevacizumab, 19 patients (17.9%)  
191 received ranibizumab, and 46 patients (43.4%) received aflibercept. At the third injection  
192 visit (n=104), 43 patients (41.3%) received bevacizumab, 17 patients (16.3%) received  
193 ranibizumab, and 44 received (41.5%) received aflibercept. At the fourth injection visit  
194 (n=99), 40 patients (40.4%) received bevacizumab, 16 patients (16.2%) received  
195 ranibizumab, and 43 patients (43.4%) received aflibercept. At one year (n=74), 25  
196 patients (33.8%) received bevacizumab, 10 patients (13.5%) received ranibizumab, and  
197 39 patients (52.7%) received aflibercept (Table 2).

198 There were relatively high adherence rates to the first injection for a patient's  
199 second, third, and fourth injections as well as at one year for both the patients who were  
200 initially started on a sample (96.2%, 95.9%, 91.9%, and 93.4% respectively) and for  
201 control patients (98.1%, 94.2%, 94.9%, 87.8%), as seen in **Table 2**.



202           There was a statistically significant difference in the distribution of anti-VEGF  
203 injections given to the sample group and to the control group at each injection visit  
204 ( $p < 0.001$  for each visit, **Table 2**). **Figure 1** demonstrates the percentage of each anti-  
205 VEGF agent at each injection visit. Bevacizumab usage was significantly lower by chi-  
206 square test in samples relative to controls in the first four injections ( $p < 0.001$  for each)  
207 and at 1 year ( $p < 0.001$ ). Ranibizumab usage was not significantly different in samples  
208 relative to controls across the first four injections ( $p = 0.48$ ,  $p = 0.73$ ,  $p = 0.44$ ,  $p = 0.66$ ) and  
209 at one year ( $p = 0.15$ ). Aflibercept use was significantly increased in samples relative to  
210 controls during the first four injections ( $p < 0.001$  for each) and at one year ( $p < 0.001$ ).

#### 211 *Time to injection from diagnosis and first retina visit*

212           Time of the first visit with a retina specialist for evaluation of nvAMD to first anti-  
213 VEGF injection was significantly different between the sample and control groups  
214 ( $p = 0.02$ ), with a mean of  $0.31 \pm 1.84$  days for the sample population and  $1.19 \pm 3.38$   
215 days for the control population (**Table 3**).

#### 216 *Visual acuity outcomes*

217           Snellen visual acuity (VA) was recorded at each injection visit. Snellen VA was  
218 converted to logMAR form. There was no significant difference between logMAR acuity  
219 in the sample group and the control group during any of the injection visits. There was  
220 no significant difference in the improvement in logMAR acuity between the sample and  
221 control group from the first to the fourth visit ( $p = 0.99$ , **Table 4**).

#### 222 *Bevacizumab use among attendings*

223           Ten attendings contributed an equal number of sample and control patients to  
224 our study. In the sample population, rates of bevacizumab use were low (ranging from

225 0% to 4.0%), with 6/10 attendings never using bevacizumab after initial injection with a  
226 sample medication. In the control population, bevacizumab usage was higher, ranging  
227 from 15.4% to 100% among all injections examined in our study (**Table 5**).

## 228 **Discussion**

229 Our study found that in patients with nvAMD treated with anti-VEGF agents,  
230 there was a high adherence to the initial agent of choice for subsequent injections.  
231 Additionally, eyes of treatment naïve nvAMD patients who were initiated on a sample  
232 anti-VEGF agent had significantly lower rates of subsequent bevacizumab use  
233 compared to patients who did not receive an initial sample anti-VEGF agent despite the  
234 same attendings initiating treatment with bevacizumab among the control eyes.

235 We found that the use of sample medications for the initial treatment of nvAMD is  
236 associated with subsequent use of the associated brand name medication in the same  
237 eye. For physicians who initiated treatment with an anti-VEGF sample, there may be  
238 various reasons to maintain patients on that same agent for subsequent injections.  
239 There may be some physicians who always prefer brand-name agents in their personal  
240 practice patterns, and access to samples may not necessarily alter their behavior.  
241 However, the control population in our study was matched by both attending physician  
242 and location of treatment to the sample group. The physicians included in our study  
243 tended to use bevacizumab as an anti-VEGF agent more frequently in the control  
244 population group relative to the sample population. One possible reason might be a  
245 hesitancy in switching to an alternative agent if the initial medication initially showed  
246 efficacy for the patient. One might also imagine that switching to a cheaper, off-label  
247 medication for a patient's second injection when they were started on an FDA-approved

248 drug that is working may be difficult to explain to a patient. Regardless of the motivating  
249 factors, the inertia from using a sample initially leads to less use of lower cost  
250 bevacizumab in the majority of patients at least up to the one year follow-up period in  
251 this study.

252 There are several ethical and financial concerns with frequent medication sample  
253 usage, and some institutions have severely limited or banned the use of samples.<sup>11</sup> One  
254 possible concern is that drug samples are a source of marketing that can have a major  
255 influence on physician prescribing behavior.<sup>12</sup> Previous studies have found that sample  
256 availability can lead physicians to prescribe drugs that are different from their preferred  
257 drug choice in an attempt to reduce costs to the patient.<sup>5</sup>

258 Furthermore, samples may contribute to rising health care costs by increasing  
259 the subsequent use of more expensive products.<sup>13,14</sup> The majority of anti-VEGF  
260 injections are for nvAMD.<sup>9</sup> Medicare Part B alone spends more than 3.5 billion dollars  
261 annually on anti-VEGF medications, with the amount steadily increasing.<sup>8</sup> The  
262 decreased utilization of bevacizumab among eyes receiving samples has significant  
263 economic ramifications for the healthcare system, given the major cost differential  
264 between the off-label medication bevacizumab versus the brand name medications  
265 aflibercept and ranibizumab.

266 Samples can, however, provide benefits to both physicians and patients. Sample  
267 medications facilitate rapid, no-cost treatment for patients and allow physicians to  
268 initiate therapy in a timely manner without the concern of incurring the financial liability  
269 of insurance denials. With sample medications, patients are able to start treatment  
270 immediately while awaiting insurance authorizations. Samples also allow treatment for

271 off-label conditions for which it can be difficult to obtain insurance approval. This is  
272 especially important in anti-VEGF medication use, as on-label medications account for  
273 significant financial cost to physicians, clinics, and potentially patients if uncovered.

274 Our study found a small, though statistically significant, difference in the mean  
275 number of days from a nvAMD patient's first visit with a retina specialist and their first  
276 injection for patients who received an initial sample compared to those who did not.  
277 Many of the major clinical trials (such as MARINA, ANCHOR, and VIEW1 and 2)  
278 demonstrating the efficacy of anti-VEGF use in nvAMD included only patients with  
279 recent or newly active exudation.<sup>15</sup> Prompt treatment with anti-VEGF agents in the  
280 setting of recent conversion is important to maximize clinical and VA outcomes, and  
281 thus sample use is truly beneficial to patients as time sensitive treatment can be  
282 initiated without concern for insurance denials of a high cost drug.

283 One potential solution that may reduce healthcare spending on anti-VEGF  
284 medications while preserving urgent access to vision-saving medication and physician  
285 choice/patient autonomy would be for insurance companies to waive PAs for  
286 bevacizumab while samples are still available for physician use in clinics. In the  
287 American Medical Association physician survey in 2020, 94% of physicians reported  
288 care delays secondary to PA requirements.<sup>16</sup> Waiving PAs may allow patients to have  
289 rapid access to a medication while also decreasing the administrative burdens on  
290 physicians and clinics. As things stand now, Repka et al. recently reported that  
291 bevacizumab use has declined over the past 7 years across all included insurance  
292 payors according to data from the Intelligent Research in Sight (IRIS) registry despite an  
293 increase in tools such as prior authorization and step therapy.<sup>17</sup>

294 Optimal anti-VEGF agent choice for nvAMD continues to be debated at length,  
295 and it is well beyond the scope and goal of our study. We are fortunate that each  
296 treatment is an effective one for nvAMD and recognize the importance of allowing both  
297 physician and patient autonomy in treatment choice. There are many clinical situations  
298 when a specific medication may not be the ideal anti-VEGF agent of choice, including  
299 limited efficacy in some patients, medication allergies, patients who are unwilling to  
300 consent to use of an off-label drug therapy, cost to patients, or physician/patient  
301 preference. Furthermore, we emphasize that the goal of our study is not to study the  
302 efficacy of a particular anti-VEGF agent, nor is it to advocate for on-label or off-label  
303 medications, but to understand the potential association of anti-VEGF sample  
304 medication use with ultimate anti-VEGF agent selection. Lastly, we do not advocate for  
305 a ban on anti-VEGF medication samples, as their availability has some benefits for  
306 patients. In all these situations, the availability of multiple anti-VEGF agents and sample  
307 medications to test their efficacy is valuable to both patient and clinician. Minimizing  
308 barriers to similarly efficacious, but lower cost options such as bevacizumab could  
309 relieve administrative burdens on physicians and staff, lead to lower healthcare  
310 spending, and may ultimately help patients obtain prompt treatment.

311 Limitations to this study include its retrospective nature. Additionally, the patient  
312 population and retina specialists are from a single institution and may not be  
313 representative of nationwide practice patterns. Another limitation is that sample  
314 utilization was only examined in patients who received an anti-VEGF sample as their  
315 initial treatment. Patients may have received samples is in the middle of their injection

316 course (for example, when a physician is considering whether to switch agents for  
317 greater efficacy), and these patients were not included in our study.

318 Our study demonstrates that when a sample anti-VEGF is the first treatment,  
319 there is persistent use of the more expensive medication in subsequent injections at  
320 least up to one year. Ophthalmologists should be cognizant of how samples may impact  
321 future medication use whether directly or indirectly due to administrative, clinical, and  
322 patient factors. Payors should also consider how requiring prior authorizations may  
323 paradoxically increase health care costs, which is detrimental to the payors directly as  
324 well as society as a whole.

325

326  
327  
328

- A. Funding/support: None  
B. Financial Disclosures:

- 329 1. JBM is a consultant for Alcon, Allergan, Carl Zeiss, Sunovion, and  
330 Genentech.  
331 2. DH is a consultant for Allergan, Genentech, Omeicos Ophthalmics, and has  
332 received financial support from Lions VisionGift, Commonwealth Grant, and  
333 Macular Society.  
334 3. LAK has received financial support from National Eye Institute and CureVac  
335 AG, has financial arrangement with Pykus Therapeutics, and holds patents  
336 through Massachusetts Eye and Ear.  
337 4. DGV is a consultant for Valitor, Olix Pharmaceuticals, and has received  
338 financial support from National Eye Institute, Research to Prevent Blindness,  
339 Loefflers Family Foundation, Yeatts Family Foundation, and Alcon Research  
340 Institute.  
341 5. DE is a consultant for Alcon, Allergan, Dutch Ophthalmics, Genentech, and  
342 Glaukos. He has a financial relationship with Alderya Therapeutics and Pykus  
343 Therapeutics, and has received financial support from Neurotech  
344 Pharmaceuticals.  
345 6. ESG has a financial relationship with Auro Biosciences, Astellas Pharma, and  
346 Valeant Pharmaceuticals.  
347 7. JWM is a consultant for Genentech/Roche, KalVista Pharmaceuticals, Ltd.,  
348 Sunovion, Heidelberg Engineering, LifeBiosciences, Inc; has received  
349 financial support from Lowy Medical Research Institute, Ltd.; has royalties  
350 with Valeant Pharmaceuticals/Mass Eye and Ear, ONL Therapeutics, LLC;  
351 Aptinyx, Inc; and holds a patent through Valeant Pharmaceuticals/Mass Eye  
352 and Ear, ONL Therapeutics, LLC.  
353 8. DMW holds a patent through Massachusetts Eye and Ear.  
354 9. RP was a consultant for Anthem Blue Cross and Blue Shield.  
355 10. All other authors (KMW, TB, SP, EC, JK, MEA, LHH, RH, SM, NAP, LS) have  
356 reported that they have no relationships relevant to the contents of this paper  
357 to disclose.

- 358 C. Other acknowledgments: The authors would like to thank Stephanie Gooltz and  
359 Fran McDonald for their help on this project.

360  
361

362  
363

364 References

- 365 1. Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to  
366 treatment in neovascular age-related macular degeneration. *Acta Ophthalmol.*  
367 2015;93(7):616-620. doi:10.1111/aos.12781
- 368 2. Rauch R, Weingessel B, MacA SM, Vecsei-Marlovits P V. Time to first treatment:  
369 The significance of early treatment of exudative age-related macular  
370 degeneration. *Retina*. Published online 2012. doi:10.1097/IAE.0b013e3182018df6
- 371 3. Petitt CE, Kiracofe E, Adamson A, Barbieri JS. Prior authorizations in dermatology  
372 and impact on patient care: An updated survey of US dermatology providers and  
373 staff by the American Academy of Dermatology. *Dermatol Online J*. Published  
374 online 2021.
- 375 4. Association AM. 2019 AMA prior authorization (PA) physician survey. Published  
376 2021. [https://www.ama-assn.org/system/files/2020-06/prior-authorization-survey-](https://www.ama-assn.org/system/files/2020-06/prior-authorization-survey-2019.pdf)  
377 [2019.pdf](https://www.ama-assn.org/system/files/2020-06/prior-authorization-survey-2019.pdf)
- 378 5. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A  
379 physician survey of the effect of drug sample availability on physicians' behavior.  
380 *J Gen Intern Med*. 2000;15(7):478-483. doi:10.1046/j.1525-1497.2000.08014.x
- 381 6. Hurley MP, Stafford RS, Lane AT. Characterizing the relationship between free  
382 drug samples and prescription patterns for acne vulgaris and rosacea. *JAMA*  
383 *Dermatology*. Published online 2014. doi:10.1001/jamadermatol.2013.9715
- 384 7. Steinbrook R. The Price of Sight - Ranibizumab, Bevacizumab, and the Treatment  
385 of Macular Degeneration. *N Engl J Med*. Published online 2006:1409-1412.
- 386 8. Glasser DB, Parikh R, Lum F, Williams GA. Intravitreal Anti-Vascular Endothelial  
387 Growth Factor Cost Savings Achievable with Increased Bevacizumab  
388 Reimbursement and Use. *Ophthalmology*. 2020;127(12):1688-1692.  
389 doi:10.1016/j.ophtha.2020.06.012
- 390 9. Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ.  
391 Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among  
392 Privately Insured and Medicare Advantage Patients. *Ophthalmology*.  
393 2017;124(3):352-358. doi:10.1016/j.ophtha.2016.10.036
- 394 10. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician  
395 prescribing patterns. *Fam Med*. 2002;34(10):729-731.
- 396 11. Rabin RC. Free Drug Samples? Bad Idea, Some Say. *The New York Times*.  
397 2007.
- 398 12. Miesner, A. R., Allen, D. P., Koenigsfeld, C. F., & Wall GC. Effect of Sample  
399 Medication Restrictions on Prescribing at a Private Clinic. *Arch Intern Med*.  
400 2009;169(13):1241-1247. doi:10.1001/archinternmed.2008.569
- 401 13. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving  
402 pharmaceutical samples and association between sample receipt and out-of-  
403 pocket prescription costs. *Med Care*. Published online 2008.  
404 doi:10.1097/MLR.0b013e3181618ee0
- 405 14. Chimonas S, Kassirer JP. No more free drug samples? *PLoS Med*. 2009;6(5):2-5.  
406 doi:10.1371/journal.pmed.1000074
- 407 15. Parikh R, Avery RL, Saroj N, Thompson D, Freund KB. Incidence of New  
408 Choroidal Neovascularization in Fellow Eyes of Patients with Age-Related  
409 Macular Degeneration Treated with Intravitreal Aflibercept or Ranibizumab. *JAMA*



- 410            *Ophthalmol.* 2019;137(8):914-920. doi:10.1001/jamaophthalmol.2019.1947  
411        16. American Medical Association. AMA Prior Authorization Survey. Published 2021.  
412            <https://www.ama-assn.org/system/files/2021-04/prior-authorization-survey.pdf>  
413        17. Repka MX, Glasser DB, Cohen CG, et al. Use of Bevacizumab Injections in  
414            Medicare Fee For Service in the IRIS® Registry (Intelligent Research in Sight).  
415            *Ophthalmol Retin.* Published online 2021:1-2. doi:10.1016/j.oret.2021.03.003  
416  
417

418 **Figure 1 Title:** Percentage use of anti-VEGF agents at each visit for sample and control  
419 groups

420 **Figure 1 Legend:** \* denote  $p < 0.001$

421

<b>Table 1: Baseline demographics of sample and control group</b>			
	<b>Sample population (n=106)</b>	<b>Control population (n=106)</b>	<b>P value</b>
<b>Gender</b>			
Male	38 (35.8%)	37 (34.9%)	0.53
Female	68 (64.2%)	69 (65.1%)	
<b>Age, mean (SD)</b>	79.7 (8.2)	79.2 (8.5)	0.89
<b>Race</b>			0.10
White	93 (87.7%)	87 (82.1%)	
Black	4 (3.8%)	0 (0%)	
Asian	0 (0%)	4 (3.8%)	
Hispanic	0 (0%)	0 (0%)	
Unavailable	9 (8.5%)	15 (14.1%)	
<b>Insurance</b>			0.06
Medicare	42 (39.6%)	78 (73.6%)	
Medicare Advantage/Private	64 (60.4%)	28 (26.4%)	
<b>Location of first injection</b>			0.93
Site 1	29 (27.4%)	29 (27.4%)	
Site 2	18 (17.0%)	18 (17.0%)	
Site 3	59 (55.7%)	59 (55.7%)	

<b>Table 2: Anti-VEGF agent selection at each injection visit and at one year</b>					
	<b>Injection 1</b>	<b>Injection 2</b>	<b>Injection 3</b>	<b>Injection 4</b>	<b>One year</b>
<b>Samples<sup>a</sup></b>					
Number of patients	106	106	97	86	61
Bevacizumab	0 (0%)	2 (1.9%)	3 (3.1%)	4 (4.7%)	0 (0%)
Ranibizumab	22 (20.8%)	21 (19.8%)	20 (20.6%)	16 (18.6%)	14 (23.0%)
Aflibercept	84 (79.2%)	83 (78.3%)	74 (76.3%)	66 (76.7%)	47 (77.0%)
Number of patients adherent to first injection	NA	102 (96.2%)	93 (95.9%)	79 (91.9%)	57 (93.4%)
<b>Controls<sup>a</sup></b>					
Number of patients	106	106	104	99	74
Bevacizumab	43 (40.6%)	41 (38.7%)	43 (41.3%)	40 (40.4%)	25 (33.8%)
Ranibizumab	18 (17.0%)	19 (17.9%)	17 (16.3%)	16 (16.2%)	10 (13.5%)
Aflibercept	45 (42.4%)	46 (43.4%)	44 (41.5%)	43 (43.4%)	39 (52.7%)
Number of patients adherent to first injection	NA	104 (98.1%)	98 (94.2%)	94 (94.9%)	65 (87.8%)
<b>Chi-Square Test for Samples vs. Controls</b>					
P value	<b>&lt;0.001</b>	<b>&lt;0.001</b>	<b>&lt;0.001</b>	<b>&lt;0.001</b>	<b>&lt;0.001</b>


<sup>a</sup> All percentages are calculated as a proportion of number of patients at that injection visit.

	<b>Sample population (n=106)</b>	<b>Control population (n=106)</b>	<b>P value</b>
<b>Number of days from first visit with a retinal specialist to first injection (mean, SD)</b>	0.31 ± 1.84	1.19 ± 3.38	<b>0.02</b>

	<b>Sample population</b>	<b>Control population</b>	<b>P value</b>
<b>Visual Acuity (LogMAR) at first visit (mean, SD)</b>	0.552 (0.369)	0.504 (0.305)	0.34
<b>Visual Acuity (LogMAR) at second visit</b>	0.440 (0.330)	0.486 (0.299)	0.40
<b>Visual Acuity (LogMAR) at third visit (mean, SD)</b>	0.443 (0.305)	0.477 (0.321)	0.47
<b>Visual Acuity (LogMAR) at fourth visit (mean, SD)</b>	0.441 (0.238)	0.442 (0.224)	0.99
<b>Change in Visual (LogMAR) between first and fourth Visit (mean, SD)</b>	-0.106 (0.577)	-0.045 (0.250)	0.48

**Table 5: Rate of bevacizumab usage among attendings within sample and control groups**

Attending	Number of patient eyes contributed in each group per attending	Samples		Controls	
		Rate of bevacizumab usage for first injection	Rate of bevacizumab usage for total injections	Rate of bevacizumab usage for first injection	Rate of bevacizumab usage for total injections
1	27	0/27 (0%)	1/122 (0.8%)	7/27 (25.9%)	33/132 (25.0%)
2	25	0/25 (0%)	4/105 (3.8%)	11/25 (44%)	35/72 (48.6%)
3	18	0/18 (0%)	3/75 (4.0%)	10/18 (55.6%)	44/86 (51.1%)
4	9	0/9 (0%)	1/35 (2.9%)	2/9 (22.2%)	6/39 (15.4%)
5	8	0/8 (0%)	0/37 (0%)	3/8 (37.5%)	12/37 (32.4%)
6	7	0/7 (0%)	0/31 (0%)	4/7 (57.1%)	18/33 (54.5%)
7	5	0/5 (0%)	0/23 (0%)	2/5 (40%)	9/21 (42.9%)
8	4	0/4 (0%)	0/18 (0%)	1/4 (25.0%)	5/20 (25.0%)
9	2	0/2 (0%)	0/8 (0%)	2/2 (100%)	9/10 (90.0%)
10	1	0/1 (0%)	0/4 (0%)	1/1 (100%)	4/4 (100%)



Preprint doi: <https://doi.org/10.1101/2021.07.27.20111010>; this version posted July 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.